Chronic Spontaneous Urticaria with Inadequate Antihistamine Response
This patient has chronic spontaneous urticaria (CSU) that is inadequately controlled on standard-dose second-generation antihistamines, and you should immediately increase the fexofenadine (Allegra) dose up to 4-fold (180 mg twice daily or 360 mg once daily) before considering additional therapies 1.
Diagnosis
The clinical presentation is consistent with chronic spontaneous urticaria (CSU):
- Generalized itching, rash, and erythema persisting for 1 year (>6 weeks defines chronicity)
- Temporary response to antihistamines (Avil/dexchlorpheniramine and Allegra/fexofenadine) with recurrence after 4 days
- No identifiable trigger despite occupational exposure to welding fumes
The elevated RBC count (6.15) warrants consideration of polycythemia vera, which can present with aquagenic pruritus, though the patient's presentation is more consistent with CSU 2.
Recommended Treatment Algorithm
Step 1: Optimize Second-Generation Antihistamine Dosing
Start with updosing fexofenadine (Allegra) to 4-fold the standard dose 1:
- Standard dose: 180 mg once daily 3
- Updosed regimen: 180 mg twice daily (total 360 mg/day) 4, 5, 6
- Alternative: 240 mg twice daily has been studied and shown effective 4, 6
The 2022 international urticaria guidelines explicitly recommend increasing second-generation H1-antihistamines up to 4-fold when standard dosing provides inadequate control after 2-4 weeks 1. This patient's 4-day response window followed by recurrence indicates subtherapeutic dosing.
Step 2: Avoid Common Pitfalls
Critical actions:
- Discontinue Avil (dexchlorpheniramine) - this first-generation antihistamine causes sedation and reduced performance without superior efficacy 7
- Avoid aggravating factors: overheating, stress, alcohol, aspirin, NSAIDs, and ACE inhibitors 7
- Consider occupational triggers: welding fumes may contain nickel and other contact allergens, though CSU typically lacks identifiable triggers 8
Step 3: If Inadequate Response After 2-4 Weeks
Add omalizumab 300 mg subcutaneously every 4 weeks 1:
- This is second-line therapy per 2022 guidelines
- Can updose to 600 mg every 2 weeks if insufficient response
- Allow up to 6 months for full therapeutic effect
Step 4: If Omalizumab Fails
Add cyclosporine 3-5 mg/kg/day (third-line therapy) 1, 7:
- Requires monitoring of blood pressure and renal function (BUN, creatinine) every 6 weeks
- Risks include hypertension, renal impairment, hirsutism, gum hypertrophy
Additional Diagnostic Considerations
Given the elevated RBC count, obtain:
- Complete blood count with differential, blood film, ESR 2
- JAK2 V617F mutation testing if polycythemia vera suspected (elevated hemoglobin/hematocrit, microcytosis, low ESR) 2
- Basic urticaria workup: C-reactive protein, total IgE, IgG-anti-TPO to assess for autoimmune CSU 1
The elevated RBC may represent secondary polycythemia from chronic hypoxia (welding environment) or essential polycythemia vera, both of which can cause pruritus 2.
Symptomatic Management
While optimizing antihistamine therapy:
- Cooling antipruritic lotions: 1% menthol in aqueous cream or calamine 7
- Emollients: Apply daily to prevent xerosis
- Short-term oral corticosteroids (prednisolone 50 mg daily for 3 days) only for acute severe exacerbations 7
- Never use long-term oral corticosteroids for chronic urticaria 7
Prognosis and Follow-up
Reassess after 2-4 weeks on updosed fexofenadine 1. The average duration of CSU is 2-5 years, with eventual spontaneous remission in most cases 7, 9. Once complete control is achieved for 3 consecutive months, consider gradual step-down by reducing the dose by no more than 1 tablet per month 1.